Forward Price-to-Revenue Multiple: Cumberland Pharma (CPIX)
Raw material shortage risks and logistical disruptions are putting pressure on the business of Cumberland Pharmaceuticals (CPIX). The company's forward P/S clearly demonstrates these fluctuations, where the value of 3.50 corresponds to the current metric. The integration of Kristalose and Caldolor into hospital standards provides stability, while production capacities continue to operate without interruption during a scheduled upgrade of packaging lines.
CPIX (cumberlandpharma.com): analytical breakdowns and indicator data
- current price and projected stock value:
- company stock exchange capitalization indicators:
- business book valuation details:
- issuer credit burden and liquidity indicators:
Total Debt to Capital Cumberland Pharmaceuticals|CPIX - Long-Term Liabilities to Capital|Short-Term Debt to Equity Cumberland Pharmaceuticals Inc.|CPIX - Aggregate Debt Obligations|Debt to Book Capitalization Ratio Cumberland Pharmaceuticals Inc.|CPIX - Company Long-Term Debt|Company Short-Term Debts Cumberland Pharmaceuticals|Quick Liquidity cumberlandpharma.com
- business earnings and investment ratios data:
CPIX - Company Profit|Projected Future Earnings Cumberland Pharmaceuticals|CPIX - Price to Earnings Multiple|Projected Price to Earnings Cumberland Pharmaceuticals|CPIX - Growth-Adjusted Payback Ratio|Enterprise Value to Earnings Before Interest, Taxes, Depreciation and Amortization Cumberland Pharmaceuticals|CPIX - Profit before deduction of interest, taxes, depreciation and amortization|Net earnings per share (EPS TTM) Cumberland Pharmaceuticals|CPIX - Earnings per share for the trailing year|Quarterly EPS earnings growth cumberlandpharma.com|CPIX - Earnings growth in current year|Net earnings per share growth forecast for next year Cumberland Pharmaceuticals
- sales and revenue data:
Summary company analysis:CPIX (Cumberland Pharma)
The stable cash flow from the hospital products of Cumberland Pharmaceuticals (CPIX) allows for an objective business valuation based on the ratio of market capitalization to expected sales. Analyzing the forward P/S metric, an investor sees a current value of 3.50, which helps determine the degree of the asset's undervaluation relative to its ability to generate revenue and service obligations over the long term.
Who Cumberland Pharmaceuticals competes with
Forward P/S Multiple HLN (Haleon PLC)|Forward P/S Multiple Kenvue Corp KVUE|Verona Pharma PLC - Forward P/S Multiple|Market Cap to Future Revenue Ratio jyongbio.com|LGND: Forward P/S Multiple|Market Cap to Projected Revenue AMRX|Price-to-Projected Revenue Ratio Perrigo Company|Market Cap to Future Revenue Ratio Alvotech ALVO|Forward P/S Multiple LQDA|GLPG: Future Price to Revenue|Forward P/S Multiple ANIP (ANI Pharmaceuticals, Inc.)|Market Cap to Expected Sales Ratio MannKind Corp (MNKD)|AMPH: Forward Price-to-Revenue Multiple|Forward Price to Sales PCRX (Pacira)|ARS Pharmaceuticals (SPRY) - Price-to-Projected Revenue Ratio|Market Cap to Projected Revenue TBPH|AQST (Aquestive Corp) - Forward P/S Multiple|Forward Price-to-Revenue Multiple scPharmaceuticals Inc. (SCPH)|Forward Price-to-Revenue Multiple TECX (Tectonic Therapeutic, Inc.)|TNXP (Tonix Pharmaceuticals Holding) - Forward Price to Sales|Price-to-Projected Revenue Ratio SXT Pharmaceuticals SXTC|Forward Price to Sales EPRX|BHST - Price-to-Projected Revenue Ratio|eXoZymes (EXOZ) - Forward Price-to-Revenue Multiple|ORMP: Forward P/S Multiple|ENTX: Price to Expected Revenue Ratio|HYFT (ipatherapeutics.com) - Forward P/S Multiple|Forward P/S Multiple ABVC BioPharma|Price-to-Projected Revenue Ratio Quantum BioPharma (QNTM)|FibroGen (FGEN) - Projected Price to Revenue|Forward P/S Multiple TELO (telomirpharma.com)|RANI - Forward Price-to-Revenue Multiple|SNYR - Price-to-Projected Revenue Ratio|rallybio.com - Price to Expected Revenue Ratio|LEXX: Forward P/S Multiple|Forward Price-to-Revenue Multiple Pulmatrix Inc|PTHL (Pheton Holdings) - Forward P/S Multiple|Market Cap to Future Revenue Ratio Aptorum Group Limited APM|Price-to-Projected Revenue Ratio Lyra Therapeutics (LYRA)|Forward Price-to-Revenue Multiple Impact BioMedical Inc IBO|Price-to-Projected Revenue Ratio tnfpharma.com TNFA|Forward Price to Sales YCBD|PainReform Ltd - Forward P/S Multiple|Altamira Therapeutics Ltd (CYTO) - Forward Price-to-Revenue Multiple|lipella.com (LIPO) - Price-to-Projected Revenue Ratio|OptiNose (OPTN) - Forward P/S Multiple|PIRS (Pieris Pharmaceuticals Inc) - Forward P/S Multiple|PROC: Forward Price to Sales|Price-to-Projected Revenue Ratio Petros Pharmaceuticals, Inc. (PTPI)|Forward P/S Multiple Qilian International Corp (QLI)|ACELYRIN, Inc. - Forward Price-to-Revenue Multiple|Forward P/S Multiple tffpharma.com TFFP
